Do analysts prefer BYSI or CODX?

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 5,478.51%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, EVAX or CODX?

Evaxion A/S has higher revenue and earnings than Co-Diagnostics. Evaxion A/S is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evaxion A/S $7.53M 3.33 -$7.71M -$1.21 N/A Co-Diagnostics $721.39K 11.71 -$46.90M -$10.32 N/A

Is EVAX or CODX more profitable?

Evaxion A/S has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Evaxion A/S's return on equity of -61.43% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% Co-Diagnostics -6,531.77% -210.99% -174.97%

Do analysts rate LTRN or CODX?

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 5,478.51%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is LTRN or CODX more profitable?

Lantern Pharma has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Co-Diagnostics -6,531.77% -210.99% -174.97%

Do analysts rate GNTA or CODX?

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 5,478.51%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, GNTA or CODX?

Genenta Science has higher earnings, but lower revenue than Co-Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Co-Diagnostics $721.39K 11.71 -$46.90M -$10.32 N/A

Co-Diagnostics (CODX) Competitors

$1.21 -0.05 (-3.97%)

As of 08/28/2026 04:00 PM Eastern

Compare

CODX vs. SGMO, BYSI, EVAX, LTRN, and GNTA

Should you buy Co-Diagnostics stock or one of its competitors? Co-Diagnostics's main competitors and comparable companies include Sangamo Therapeutics (SGMO), BeyondSpring (BYSI), Evaxion A/S (EVAX), Lantern Pharma (LTRN), and Genenta Science (GNTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Co-Diagnostics compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Sangamo Therapeutics has a net margin of -310.81% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sangamo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.87, indicating that its stock price is 187% more volatile than the broader market.

Co-Diagnostics has lower revenue, but higher earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Co-Diagnostics	$721.39K	11.71	-$46.90M	-$10.32	N/A

In the previous week, Co-Diagnostics had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 1 mentions for Co-Diagnostics and 0 mentions for Sangamo Therapeutics. Co-Diagnostics' average media sentiment score of 0.93 beat Sangamo Therapeutics' score of 0.00 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Co-Diagnostics	Positive

Sangamo Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 5,478.51%. Given Sangamo Therapeutics' higher possible upside, equities research analysts plainly believe Sangamo Therapeutics is more favorable than Co-Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Co-Diagnostics beats Sangamo Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Co-Diagnostics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BeyondSpring has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. BeyondSpring's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

BeyondSpring has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market.

Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 5,478.51%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, BeyondSpring and BeyondSpring both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.89 beat Co-Diagnostics' score of 0.93 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Co-Diagnostics	Positive

BeyondSpring has higher earnings, but lower revenue than Co-Diagnostics. BeyondSpring is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	N/A	N/A	-$1.01M	-$0.12	N/A
Co-Diagnostics	$721.39K	11.71	-$46.90M	-$10.32	N/A

Summary

BeyondSpring beats Co-Diagnostics on 8 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Evaxion A/S has higher revenue and earnings than Co-Diagnostics. Evaxion A/S is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.33	-$7.71M	-$1.21	N/A
Co-Diagnostics	$721.39K	11.71	-$46.90M	-$10.32	N/A

Evaxion A/S has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Evaxion A/S's return on equity of -61.43% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evaxion A/S has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market.

Evaxion A/S currently has a consensus price target of $11.00, indicating a potential upside of 265.45%. Co-Diagnostics has a consensus price target of $67.50, indicating a potential upside of 5,478.51%. Given Co-Diagnostics' higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Evaxion A/S had 7 more articles in the media than Co-Diagnostics. MarketBeat recorded 8 mentions for Evaxion A/S and 1 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.93 beat Evaxion A/S's score of -0.13 indicating that Co-Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Evaxion A/S	Neutral
Co-Diagnostics	Positive

Summary

Evaxion A/S beats Co-Diagnostics on 10 of the 17 factors compared between the two stocks.

How does Co-Diagnostics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Lantern Pharma has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.87, meaning that its share price is 187% more volatile than the broader market.

Lantern Pharma has higher earnings, but lower revenue than Co-Diagnostics. Lantern Pharma is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Co-Diagnostics	$721.39K	11.71	-$46.90M	-$10.32	N/A

Lantern Pharma has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Co-Diagnostics' return on equity of -210.99% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 5,478.51%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Co-Diagnostics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Lantern Pharma and Lantern Pharma both had 1 articles in the media. Lantern Pharma's average media sentiment score of 1.89 beat Co-Diagnostics' score of 0.93 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Lantern Pharma	Very Positive
Co-Diagnostics	Positive

Summary

Co-Diagnostics beats Lantern Pharma on 8 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Genenta Science has higher earnings, but lower revenue than Co-Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Co-Diagnostics	$721.39K	11.71	-$46.90M	-$10.32	N/A

Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the broader market.

In the previous week, Genenta Science had 1 more articles in the media than Co-Diagnostics. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for Co-Diagnostics. Genenta Science's average media sentiment score of 0.94 beat Co-Diagnostics' score of 0.93 indicating that Genenta Science is being referred to more favorably in the media.

Company	Overall Sentiment
Genenta Science	Positive
Co-Diagnostics	Positive

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 2.3% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Co-Diagnostics has a consensus target price of $67.50, suggesting a potential upside of 5,478.51%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Genenta Science has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Genenta Science's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%

Summary

Genenta Science beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.45M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.12	11.62	273.16	25.45
Price / Sales	11.71	1,293.26	604.87	76.92
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	0.66	16.53	12.98	6.14
Net Income	-$46.90M	-$22.80M	$3.48B	$348.86M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	-22.44%	9.80%	7.08%	4.13%
1 Year Performance	-87.77%	55.66%	24.67%	15.17%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	2.0335 of 5 stars	$1.21 -4.0%	$67.50 +5,478.5%	-87.8%	$8.45M	$721.39K	N/A	100	Gap Down
SGMO Sangamo Therapeutics	0.9618 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
BYSI BeyondSpring	0.408 of 5 stars	$0.72 +1.6%	N/A	-61.3%	$29.62M	$1.75M	N/A	80	Positive News Gap Down
EVAX Evaxion A/S	2.0197 of 5 stars	$3.35 -1.5%	$11.00 +228.4%	+9.5%	$27.94M	$7.53M	N/A	60	Analyst Revision
LTRN Lantern Pharma	0.7219 of 5 stars	$2.18 +3.3%	N/A	-49.3%	$27.86M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. SGMO, BYSI, EVAX, LTRN, and GNTA

How does Co-Diagnostics compare to Sangamo Therapeutics?

Summary

How does Co-Diagnostics compare to BeyondSpring?

Summary

How does Co-Diagnostics compare to Evaxion A/S?

Summary

How does Co-Diagnostics compare to Lantern Pharma?

Summary

How does Co-Diagnostics compare to Genenta Science?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. SGMO, BYSI, EVAX, LTRN, and GNTA

How does Co-Diagnostics compare to Sangamo Therapeutics?

Is SGMO or CODX more profitable?

Do institutionals and insiders hold more shares of SGMO or CODX?

Which has more risk & volatility, SGMO or CODX?

Which has better earnings & valuation, SGMO or CODX?

Does the media prefer SGMO or CODX?

Do analysts prefer SGMO or CODX?

Summary

How does Co-Diagnostics compare to BeyondSpring?

Do insiders & institutionals believe in BYSI or CODX?

Is BYSI or CODX more profitable?

Which has more volatility and risk, BYSI or CODX?

Do analysts prefer BYSI or CODX?

Does the media refer more to BYSI or CODX?

Which has better valuation and earnings, BYSI or CODX?

Summary

How does Co-Diagnostics compare to Evaxion A/S?

Which has higher earnings & valuation, EVAX or CODX?

Is EVAX or CODX more profitable?

Do institutionals and insiders believe in EVAX or CODX?

Which has more risk & volatility, EVAX or CODX?

Do analysts prefer EVAX or CODX?

Does the media refer more to EVAX or CODX?

Summary

How does Co-Diagnostics compare to Lantern Pharma?

Which has more risk and volatility, LTRN or CODX?

Which has preferable earnings & valuation, LTRN or CODX?

Is LTRN or CODX more profitable?

Do insiders & institutionals hold more shares of LTRN or CODX?

Do analysts rate LTRN or CODX?

Does the media refer more to LTRN or CODX?

Summary

How does Co-Diagnostics compare to Genenta Science?

Which has better valuation and earnings, GNTA or CODX?

Which has more risk and volatility, GNTA or CODX?

Does the media refer more to GNTA or CODX?

Do institutionals and insiders have more ownership in GNTA or CODX?

Do analysts rate GNTA or CODX?

Is GNTA or CODX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools